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Abstract
Tuberculosis is still a major problem in some developed and developing countries. The poor
compliance to the treatment of tuberculosis patients due to the adverse events was supposed
to be an important factor contributing to the high prevalence. This review aims to clarify the
role and the pharmacological mechanism of the genes involved in the isoniazid-induced
hepatotoxicity. We selected English articles of studies in human from PubMed up to May 2014
with the keywords pharmacogenetic, isoniazid and hepatotoxicity, N-acetyl transferase 2 (NAT2),
CYP2E1 and glutathione S transferase (GST). Polymorphisms of NAT2, CYP2E1 and GST1 could
increase patients’ susceptibility to isoniazid-induced hepatotoxicity. The rapid acetylators of
NAT2 and rapid metabolizers of CYP2E1 showed increased concentrations of hepatotoxic
metabolites. However, the rapid metabolizers of GST1 could decrease the concentration of
hepatotoxic metabolites. Some studies of human leukocyte antigen (HLA), Uridine 50-dippho-
spho (UDP) glucuronosyltransferase (UGT), nitric oxide synthase (NOS), Broad complex,
Tramtrack, Bric-a-brac (BTB) and cap’n’collar type of basic region leucine zipper factor family
(CNC) homolog (BACH) andMaf basic leucine zipper protein (MAFK) polymorphisms showed their
roles in isoniazid-induced hepatotoxicity by modifying the expression of antioxidant enzymes.
A better insight into the role of polymorphisms of HLA, UGT, NOS, BACH and MAFK in addition
to NAT2, CYP2E1 and GST1 in the hepatotoxicity of isoniazid may support physicians in monitor-
ing patients hepatotoxicity symptoms and laboratory data and optimizing pharmacotherapy.
Future studies about the role of such polymorphisms in different ethnicities are suggested.
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Introduction
Tuberculosis is still a major problem in many countries over
the world, especially in developed and developing countries
(Cai et al., 2012). The ‘‘WHO’’ reported that there were 9
million TB sufferers annually (Anonymous, 2014). Currently,
the problem of tuberculosis has become complex with the
prevalence of multi-drug resistant tuberculosis, which reaches
600 000 cases in central Asian countries. One of the causes
of the high prevalence of multi-drug resistant tuberculosis is
presumed to be the poor compliance of patients, which
reflected the treatment failure (Singla et al., 2014; Sotgiu &
Migliori, 2014). The poor patients’ compliance to the
first-line treatment for tuberculosis, which are rifampicin,
isoniazid, pyrazinamide and ethambutol, could partly be
caused by the occurrence of liver injury as adverse event
(Babalik et al., 2012; Huang, 2007; Li et al., 2013;
Wada, 2001).
Among the oral antituberculosis drugs, isoniazid caused in
15–20% of the patients an increase in alanine and aspartate
transaminase, and in about 1% of the patients’ hepatotoxicity
was observed (Lee, 1995; Metushi et al., 2011).
The hepatotoxicity prevalence due to the isoniazid might be
predicted by age, acetylator status, alcohol use and rifampicin
use in an additional fashion (Steele et al., 1991). Rifampicin
was proposed to stimulate the activities of amidase and
CYP2E1, thus increasing the isoniazid-induced hepatotoxicity
(Huang, 2014; Hussain et al., 2003). Currently, by affecting
the isoniazid metabolism, genetic factors are also supposed to
play a role in the isoniazid-induced hepatotoxicity (Metushi
et al., 2011). Some patient characteristics like age, alcohol
use and nutrition status were also general risk factors of
antituberculosis-induced hepatotoxicity (Babalik et al, 2012;
Roy et al., 2008).
Many reviews show the proposed isoniazid metabolism
pathway (Huang, 2014; Metushi et al, 2011; Roy et al, 2008);
however, there is no review about the pharmacological
mechanisms of the genes involved in the hepatotoxicity of
isoniazid, which could be related to the isoniazid metabolism.
The genes mostly examined to understand the association
between gene polymorphism and isoniazid-induced hepato-
toxicity are N-acetyl transferase 2 (NAT2), CYP2E1 and
glutathione S transferase 1 (GST1) (Cai et al., 2012; Huang,
2007, 2014; Li et al., 2013; Metushi et al., 2011; Roy et al.,
2008; Singla et al., 2014; Steele et al., 1991; Teixeira et al.,
2007). Isoniazid is a derivative of hydrazine, which is
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hepatotoxic. There are two metabolites of isoniazid, hydra-
zine and acetylhydrazine, which are primarily involved in the
mechanism of isoniazid-induced hepatotoxicity (Figure 1).
The proposed metabolic pathways are the hydrolysis of
isoniazid into hydrazine and isonicotinic acid and the
acetylation of isoniazid into acetylisoniazid by NAT2. The
next role of NAT2 is acetylation of hydrazine into
acetylhydrazine (monoacetylhydrazine). Hydrazine and acet-
ylhydrazine are known as toxic agents, thus they should be
acetylated into non-toxic agents. Acetylhydrazine is metabo-
lized into reactive acylating intermediates, which can bind
covalently to tissue macromolecules and can cause Isoniazid-
induced hepatotoxicity (Timbrell et al., 1980). A role of GST
is to detoxify the toxic metabolites (Metushi et al., 2011; Roy
et al., 2008). To date, the role of human leukocyte antigen
(HLA) and superoxide dismutase (SOD) in the isoniazid
metabolism is still being explored (Boelsterli & Lee, 2014;
Du et al., 2013). Some genetic variants could interfere with
the activity of the enzymes.
Metushi et al. (2014) found anti-Isoniazid antibodies and
antibodies against CYP2E1, CYP3A4 and CYP2C9 in
patients with isoniazid-induced liver injury. Isoniazid was
found to form covalent adducts with CYP2E1, CYP3A4 and
CYP2C9. This suggests that the immune system is involved in
the Isoniazid-induced liver injury. Furthermore, it is sug-
gested that mild cases of Isoniazid-induced liver injury
resolve with immune tolerance and only when this immune
tolerance fails more severe liver injury results.
This review is intended to shed more light on the role and
the mechanism of the genes, which seem to be involved in the
isoniazid-induced hepatotoxicity. The novelty of our study is
that we add the pharmacological mechanism of some genes
involved in the expression of reactive oxygen species (ROS)
associated with the isoniazid-induced hepatotoxicity.
Methods
We selected English articles of studies in human from
PubMed with the keywords Pharmacogenetic AND Isoniazid
AND hepatotoxicity. We found eight articles with two articles
reviewing pharmacogenomic and genetic variations in anti-
tuberculosis-induced hepatotoxicity or liver injury (Huang,
2014; Roy et al., 2008). However, to obtain the articles on the
pharmacological mechanism of some genes related to the
isoniazid-induced hepatotoxicity, we searched in PubMed
with the keywords isoniazid AND pharmacogenetic AND
NAT2, isoniazid AND pharmacogenetic AND CYP2E1,
isoniazid AND GST, isoniazid AND HLA, isoniazid AND
HLA AND pharmacogenetic, isoniazid AND pharmacoge-
netic AND NAT2 AND CYP2E1 AND GST, isoniazid AND
NAT2 AND CYP2E1 AND GST, as well as isoniazid
AND polymorphism AND NAT2 AND CYP2E1 AND
GST. Figure 2 shows the search strategy for retrieving articles
related to the above-mentioned keywords. We limited the
search strategy up to May 2014.
Results and discussion
Regarding the search strategy for pharmacogenetics of
isoniazid-induced hepatotoxicity, we found eight articles,
but we limited the articles to the human species, thus we only
retrieved five articles. According to the search strategy of the
pharmacological mechanism of some genes related to the
isoniazid-induced hepatotoxicity, we found 30 articles related
to NAT2 and 25 articles related to human species, 6 articles
related to CYP2E1 with 5 articles among them were related to
the human species. There were 20 articles related to GST
with 7 articles among them related to the human species,
29 articles related to HLA and 3 articles related to the
polymorphisms of HLA with 27 and 2 articles among them
related to the human species, respectively. Furthermore, it was
only 1 review article related to the three genes, 5 articles with
1 review article and 4 articles related to the isoniazid and
polymorphisms of the three genes in the human species.
Pharmacological mechanisms of isoniazid-induced
hepatotoxicity
In the proposed isoniazid metabolism pathway, NAT2 has a
role in the acetylation of isoniazid to acetylisoniazid, which
will be hydrolyzed to acetylhydrazine. CYP2E1 oxidizes
Figure 1. Pathways of metabolism of isonia-
zid (adapted from Huang, 2007; Roy, 2008).
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acetylhydrazine into toxic agents. These toxic agents are
detoxified by GST by conjugation (Huang, 2007). Isoniazid
has a role in the imbalance between pro-oxidant and anti-
oxidant activity. It can both stimulate the pro-oxidant level or
decrease the level of anti-oxidant (Boelsterli & Lee, 2014).
The ROS was proposed to be associated with isoniazid-
induced hepatotoxicity by producing the oxidative stress
(Bhadauria et al., 2007; Chowdhury et al., 2006). Mechanisms
that were proposed were the damage of enzyme by superoxide
resulting from molecular oxygen reduction, the inflammatory
response of the immune system and the increase of mito-
chondrion dysfunction (Bhadauria et al., 2010; Boelsterli &
Lee, 2014). With respect to ROS, hydrazine can produce
oxygen radicals or superoxide, which can disrupt proteins and
cause degradation of polypeptide chains (Timperio et al.,
2005). Superoxide was found to be increased along with the
isoniazid treatment.
With respect to the mitochondrion activity, isoniazid can
translocate cytochrome c from the mitochondrion to the
cytosol. This translocation can alter the mitochondrion
permeability and start the hepatotoxic pathway in isoniazid
treatment (Bhadauria et al., 2010). ROS was also produced in
HepG2 cells in which NAT2 and CYP2E1 were expressed.
The low expression of HepG2 cells explained the slow
alteration of isoniazid into metabolites. This condition
resulted in a high concentration of isoniazid, which means
that the risk of occurrence of isoniazid-induced hepatotoxicity
is increased (Bhadauria et al., 2010; Brandon et al., 2003).
Some of the mitochondrial defects which was discussed could
be due to a limited number of carbon-centered reactive
intermediates that contribute to the aberrant redox chemistry
additional to ROS.
Isoniazid was hydrolyzed into hydrazine and isonicotinic
acid. Hydrazine and its derivatives were oxidized by the
enzyme systems of cytochrome P-450 (NADPH-dependent
hydrazine oxidase) and NADPH-independent hydrazine oxi-
dase (Coomes & Prough, 1983). Cytochrome P-450 and
monoamine oxidase oxidize the nitrogen of hydrazine and its
derivatives. In addition, cytochrome P-450 also removes
nitrogen of monoalkylhydrazines (Erikson & Prough, 1986).
In this way, monoalkylhydrazines are converted into
hydrocarbon forms with involvement of oxygen and a
NADPH-regenerating systems. Monoalkylhydrazines rapidly
form monoalkyldiazene intermediates leading to the forma-
tion of alkane and nitrogen using free radicals (Prough et al.,
1969).
With respect to the role of alkane production cytochrome
P450 metabolism, it should be mentioned that for iproniazid
is shown that reactive metabolites involved in the hepatotox-
icity are propane and propylene (Moloney et al., 1985). These
metabolites could be react as GST’s substrates, which would
increase the toxicity of iproniazid by decreasing the
GSH levels and also by the inhibiting GST’s function
(Spearman et al., 1984).
Furthermore, hydrazine and some derivatives also
decreased the function of cytochrome P-450, which
was demonstrated by the loss of enzyme activity in the
hepatocyte during the preincubation with hydrazine deriva-
tives (Wiebkin et al., 1982).
Related to the oxidative stress, isoniazid not only can
produce ROS but also can interfere with glucose-6-phosphate
dehydrogenase (G6PD). G6PD can protect the eukaryotic
cells from ROS activity. The mechanism of protection is
proposed by the regeneration of glutathione from glutathione
disulfide. Glutathione can protect the cells from oxidative
stress (Bhadauria et al., 2007, 2010). However, hydrazine can
decrease the glutathione formation directly and can also
reduce the expression of G6PD. This mechanism can alter the
antioxidant activity of glutathione (Bhadauria et al., 2007).
Besides the mechanism of G6PD as antioxidant, SOD,
also has antioxidant activity by catalyzing the conversion
of superoxide radical anions to hydrogen peroxide (H2O2)
(Du et al., 2013).
H2O2 is a strong oxidizing agent that can cause oxidative
damage and generate ROS. Isoniazid can diminish the
catalase activity of SOD, resulting in the accumulation of
H2O2 (Bhadauria et al., 2007).
Besides the role of ROS, the distraction of endogenous
metabolism by isoniazid metabolites was proposed to be
involved in the isoniazid hepatotoxicity. Hydrazine as a
reactive metabolite of isoniazid could react to some endogen-
ous factors. One of this mechanisms was known as the
Figure 2. Secrch strategy for retrieving the
articles.
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reaction to diminish the Mycobacterium tuberculosis by the
formation of Isoniazid-Nicotinamide Adenine Dinucleotide
(INH-NAD+). The INH-NAD+ is hydrolyzed into 4-isonico-
tinoylnicotinamid (4-INN), which can be found in the urine
after two months treatment with isoniazid. The formation of
4-INN was supposed to be related with the loss of nicotinic
acid, which can cause isoniazid hepatotoxicity (Boelsterli &
Lee, 2014; Mahapatra et al., 2012).
HLA is a gene that has a role in the human immune system
and is suspected as a gene, which has association with
isoniazid hepatotoxicity. However, the mechanism of associ-
ation is still unclear (Boelsterli & Lee, 2014; Huang, 2014). A
summary of the pharmacological mechanisms of isoniazid
induced hepatotoxicity is presented in Figure 3.
Genetic variations associated with isoniazid-induced
hepatotoxicity
The most published genetic variations involved in isoniazid-
induced hepatotoxicity were in NAT2, CYP2E1 and GST1
(Cai et al., 2012; Huang, 2014). Genetic variations involved in
isoniazid-induced hepatotoxicity are listed in Table 1.
NAT2 metabolized isoniazid into acetylisoniazid and it
was hydrolyzed into acetylhydrazine, which will be oxidized
by CYP2E1 into some hepatotoxic metabolites (Huang,
2014). The previous study in Japanese showed that patients
who were rapid acetylators had elevated serum transamino-
transferases. The rapid acetylators will quickly metabolize
isoniazid into hepatotoxic agents, which was shown by the
increase of serum transaminotransferases (Yamamoto et al.,
1986). In slow acetylators, it was demonstrated that acetyl-
ation of acetylisoniazid into diacetylisoniazid leads to non
toxic agents (Lauterburg et al., 1985). Thus, both the rapid
and slow acetylators had significant contributions to the
mechanism of isoniazid-induced hepatotoxicity (Lauterburg
et al., 1985; Peretti et al., 1987). Currently, the studies showed
that the slow acetylators had a higher risk of isoniazid-
induced hepatotoxicity than rapid acetylators (Huang, 2007;
Lee et al., 2010; Singla et al., 2014). The NAT*2 is wild-type
and is known as the highest activity variant (Cai et al., 2012;
Gupta et al., 2013). The other variants of NAT2, such as
NAT2*5, NAT2*6 and NAT2*7, are known as decreased
activity alleles. The availability of variant alleles, such as two
variants of decreased activity alleles, one variant of decreased
activity allele and two wild-type could be phenotyped into
slow acetylators, intermediate acetylators and rapid acetyla-
tors, respectively (Huang, 2007; Roy et al., 2008; Xiang et al.,
2014). A study in China showed that most of the patients
recruited in the study were intermediate acetylators (37%),
followed by slow acetylators (24%) and rapid acetylators
(15%) (Xiang et al., 2014). This study is also in accordance
with other reviews and studies, which showed that Chinese
and Japanese as a part of the Asian ethnicity have a high
frequency of intermediate acetylators. However, populations
from India showed in most of the patients the slow acetylator
genotype (Roy et al., 2008). The high frequency of slow
acetylators and intermediate acetylators in the Asian popula-
tion showed that these populations are more susceptible for
isoniazid-induced hepatotoxicity (An et al., 2012; Huang,
2014). There are 36 variants of the NAT2 gene identified
in human populations with seven most common SNPs
forming the variations (Teixeira et al., 2007; Zang et al.,
2007). Considering the high polymorphism of the NAT2 gene,
the occurrence of isoniazid-induced toxicity will be more.
CYP2E1 oxidizes the acetylhydrazine into hepatotoxic
agents. Isoniazid and hydrazine could inhibit CYP2E1
activity, and isoniazid could also inhibit the variant of
CYP2E1 with a lower activity than the wild type (Roy et al.,
2008). The polymorphisms of CYP2E1 were detected by PstI,
RsaI and DraI restriction enzymes (Huang et al., 2003). The
variant alleles RSAI and PstI+ are translated into c1 and c2.
Furthermore, the wild-type of c1, the variants of c2 and the
DraI are known as CYP2E1*1A, CYP2E1*5 and CYP2E1*6.
These variants showed increased activity (Roy et al., 2008).
According to the previous studies, the presence of homozy-
gous *1A/*1A was high in India and less frequent in China.
However, variants could increase the individual susceptibility
to the isoniazid-induced hepatotoxicity (An et al., 2012;
Roy et al., 2008).
GST is encoded by GSTM1, GSTT1 and GSTP1 (Strange
et al., 2001). The presence of null homozygous of GSTM1
and GSTT1 may cause decreased enzyme activity thereby
decreasing the detoxification of hepatotoxic metabolites.
The frequencies of null homozygous of GSTM1 and
GSTT1 among the Asian population were heterogeneous.
The frequencies of null homozygous GSTM1 in Chinese,
Malaysian and Indians were 35–63%, 62–100% and 20–79%,
respectively. However, the frequencies of null homozygous
in GSTT1 were 58%, 38% and 3–39% in those particular races
(Huang, 2007, 2014; Roy et al., 2008).
The high concentration of ROS due to hydrazine’s activity
should be reduced by manganese SOD (MnSOD). It was
found that patients heterozygous and homozygous for the
mutant allele in the 47 position of the MnSOD gene
experienced higher risk of antituberculosis induced hepato-
toxicity (Huang, 2014; Huang et al., 2007).
Figure 3. Pharmacological mechanisms of isoniazid induced hepatotox-
icity (adapted from Boelsterli & Lee, 2014).
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Other possible genetic variations mechanisms involve
HLA, UDP glucuronosyltransferase (UGT), nitric oxide
synthase (NOS), BNB and CNC homolog (BACH) and Maf
basic leucine zipper protein (MAFK). The last three enzymes
are supposed to be involved in the antioxidant activity, and
HLA is involved in the immunological reaction (Huang, 2014;
Nanashima et al., 2012).
The principal product of heme catabolism, bilirubin, is
eliminated by a conjugation reaction with glucuronic acid.
The glucuronidation reaction is mediated by UGT. Currently,
there are 15 isoforms of UGT in human, and 8 of these are
encoded by UGT1A. An increase of bilirubin was supposed to
be related with the insertion of TA in the UGT1A, which
encodes UGT1A1. This insertion inhibits the bilirubin
glucuronidation (Zucker et al., 2001). In the Taiwan popula-
tion, it was shown that the variants of UGT1A were associated
with antituberculosis-induced hepatotoxicity (Chang et al.,
2012).
The high concentration of ROS should be eliminated by
enzymes like GST, NQO1 (NAD(P)H dehydrogenase quin-
one) and heme oxygenase. The activation of these enzymes
must be supported by the mechanisms of activation and
repression of antioxidant pathways. These mechanisms will
support the transcriptional regulation of antioxidant enzymes
(Nanashima et al., 2012). During high concentrations of ROS,
MAFK can associate with antioxidant-responsive elements
(ARE), which allows the antioxidant enzymes expression. On
the contrary, the association of BACH with ARE prevents the
association between MAFK and ARE and results in the
repression of antioxidant enzymes (Nanashima et al., 2012;
Oyake et al., 1996). NO is one of the reactive nitrogen
species, which is produced by NOS. If NOS is available in the
cells, the inducible isoform of NOS (iNOS) will be
upregulated. iNOS is encoded by NOS2A, therefore by this
mechanism the increased activity of the NOS2A variant could
result in the overproduction of NO (Jaeschke et al., 2003;
Nanashima et al., 2012).
In the Japanese population, it was shown that the CC
genotype of rs11080344 in NOS2A, the CC genotype at
rs11080344 in BACH1, and the heterozygous and homozy-
gous mutant genotype at rs4720833 in MAFK were associated
with the occurrence of antituberculosis drugs-induced hep-
atotoxicity (Nanashima et al., 2012).
HLA is possibly involved in the resistance or susceptibility
to tuberculosis. It is responsible for the presentation by T cells
which initiate the protective immune response. It was shown
that the high frequency of HLA class I could influence the TB
treatment outcome. Its mechanism could be related with
recognizing the common epitope in the peptide-binding
and regulating NK cells activity (Balamurugan et al., 2004).
One study showed that the presence of HLA-DQB1*0201 and
the absence of HLA-DQA1*0102 are risk factors for drug-
induced hepatotoxicity (Sharma et al., 2002).
Conclusion
Many studies showed that the polymorphisms of NAT2,
CYP2E1 and GST1 could influence the concentration of
hepatotoxic isoniazid metabolites in the blood. Some of the
gene polymorphisms of HLA, UGT, NOS, BACH and MAFK
are supposed to contribute to isoniazid-induced hepatotoxicity
by modifying the antioxidant enzyme expression. However,
the studies which explored this mechanism are still limited. A
better insight into the role of polymorphisms in the hepato-
toxicity of isoniazid may support physicians in monitoring
patients hepatotoxicity symptoms and laboratory data and
optimizing pharmacotherapy. Future studies about the role of
such polymorphisms in different ethnicities are suggested.
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